Literature DB >> 7494500

Antibody responses raised against a conformational V3 loop peptide of HIV-1.

H Bukawa1, J Fukushima, K Hamajima, M Kimura, T Tsuji, K Q Xin, K Okuda.   

Abstract

The amino acid sequence of the principal neutralizing determinant (PND) of 224 cases of human immunodeficiency virus type 1 (HIV-1) was determined and the most frequently occurring sequence was used as a peptide antigen for studying virus-specific antibody responses. In our present study, a linear peptide of the most frequent PND was first synthesized and then oxidized to create a disulfide-bridged loop conformation. Then, in order to construct a macromolecular structure for the purpose of increasing antigenicity, the synthetic peptide was conjugated to a core peptide. We compared the immunogenicity of the disulfide-bridged loop PND peptide antigen (AG4) and the linear PND peptide antigen (AG5). After immunizing rabbits 5 and 6 times with both peptides, the results obtained using ELISA revealed that AG4 (conformational-loop type) was more capable of inducing a high titer of antigen-specific antibodies than was AG5 (linear type). Despite an amino acid sequence homology of 72%, a 1:8 dilution of serum raised against AG4 inhibited 81.9% of HIV-1IIIB-mediated cell fusion, suggesting that conformational V3 loop peptide is able to elicit an antibody response which is strongly HIV-1-specific.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7494500     DOI: 10.1111/j.1348-0421.1995.tb02249.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  2 in total

1.  HIV-1-specific cell-mediated immunity is enhanced by co-inoculation of TCA3 expression plasmid with DNA vaccine.

Authors:  T Tsuji; J Fukushima; K Hamajima; N Ishii; I Aoki; H Bukawa; Y Ishigatsubo; K Tani; T Okubo; M E Dorf; K Okuda
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

2.  Cross-linking of Fas by antibodies to a peculiar domain of gp120 V3 loop can enhance T cell apoptosis in HIV-1-infected patients.

Authors:  F Silvestris; S Nagata; P Cafforio; N Silvestris; F Dammacco
Journal:  J Exp Med       Date:  1996-12-01       Impact factor: 14.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.